Printer Friendly

Clinical.

Clinical: Point-of-care testing (POCT) is contributing to the growth of the diagnostics product market. In the first six months of this year, the FDA approved 152 POC tests. LnteLab estimates that POCT represented 35% of the in vitro diagnostics market in 2005 and that, by 2011, it will account for 41%. In 2005, the market for POCT products was worth nearly $10.5 billion. According to a FDA official, POCT manufacturers are increasingly interested in CLIA (Clinical Laboratory Improvement Amendments) wavers, as approximately 60% of labs that are CLIA certified are waived labs. In addition, FDA's revised guidance for CLIA waivers released in January more directly addresses POCT.

Source: Clinical Laboratory News

COPYRIGHT 2008 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry Watch
Publication:Instrument Business Outlook
Article Type:Brief article
Geographic Code:1USA
Date:Sep 30, 2008
Words:112
Previous Article:All four IBO indexes follow market's decline.
Next Article:Biotechnology.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters